Health Trials

B-cell Non-Hodgkin Lymphoma (B-NHL)

3

Review clinical trials related to B-cell Non-Hodgkin Lymphoma (B-NHL). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

This open-label, single arm phase 1 trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL). This trial will determine the maximum tolerated dose of CD19x22 CAR T cells using a standard 3+3 trial design.

Participants needed: 68
Trial details
Phase: Phase 1Age: 16+Biological sex: AllType: InterventionalSponsor: University of Colorado, DenverUpdated: Dec 24, 2025Locations: 1
Eligibility criteria

Subjects must not have any signs or symptoms of CNS disease or detectable eviden... [+22]

Age < 16 years of age. [+32]

Read more
Status: Recruiting

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

Participants needed: 80
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Cellectis S.A.Updated: Aug 24, 2025Locations: 10
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 [+7]

Prior use of an investigational product (except for cell or gene therapies and M... [+20]

Read more
Status: Recruiting

An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

The purpose of this study is to determine whether AcNK-Sup003 cell injection is safe and effective in the treatment of elapsed or refractory B-cell non-Hodgkin's lymphoma.

Participants needed: 13
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUpdated: Nov 19, 2024Locations: 1
Eligibility criteria

Signed an informed consent form in writing and is able to comply with the visits... [+14]

Primary central nervous system lymphoma, or active central nervous system involv... [+16]

Read more